Who is eligible for clinical trial NCT04508049?

Participants must meet protocol criteria for Hypertension. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04508049 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-10-10

A Study to Evaluate Renal Fibrosis Using MRI Techniques (NCT04508049)

🔵 Active, Not Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Mayo Clinic

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate whether or not an MRI technique (quantitative magnetization transfer or qMT) in narrowing human kidneys is feasible, reproducible, and predicts recovery.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (19 items).

Location: Mayo Clinic in Rochester — Rochester, Minnesota

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Between ages 40 and 80 years old.
Patients with hypertension (BP\>140/90 mmHg) and/or requirement for two or more antihypertensive medications for more than 4 weeks.
Serum creatinine under 2.2 and 2.0 mg/dL for men and women, respectively (Caucasians). Values for African-American subjects are slightly higher (2.4 mg/dL, males; 2.1 mg/dL females).
No contraindications to angiography: severe contrast allergy.
No contraindications to no-contrast MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia.
Patients have the ability to comply with protocol
Patients are competent and able to provide written informed consent

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patient has serum creatinine \>2.2 mg/dL for men and \>2.0 mg/dL for women (Caucasians); \>2.4 mg/dL for men and \>2.1 mg/dL for women (African American).
RVD in a solitary kidney
Patients have clinically significant medical conditions within the prior six months: e.g. myocardial infarction, congestive heart failure, stroke, that would, in the opinion of the investigators, compromise the safety of the patient.
Uncontrolled hypertension (Systolic BP \>180 mmHg despite therapy).
Diabetes requiring insulin or oral hypoglycemic medications.
Evidence of hepatitis B or C, or HIV infection.
Requirement for potentially nephrotoxic drugs; e.g., non-steroidal anti-inflammatory drugs.
Cardiac ejection fraction less than 30%.
History of deep venous thrombosis within 3 months of enrollment.
Kidney transplant.
Pacemaker, implantable defibrillator or other contraindication to MRI

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Mayo Clinic in Rochester — Rochester, Minnesota

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗